WO2003033520A3 - Anticancer vaccine and diganostic methods and reagents - Google Patents
Anticancer vaccine and diganostic methods and reagents Download PDFInfo
- Publication number
- WO2003033520A3 WO2003033520A3 PCT/US2002/030289 US0230289W WO03033520A3 WO 2003033520 A3 WO2003033520 A3 WO 2003033520A3 US 0230289 W US0230289 W US 0230289W WO 03033520 A3 WO03033520 A3 WO 03033520A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- protein
- provides
- apcs
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 4
- 108050006400 Cyclin Proteins 0.000 abstract 3
- 102000016736 Cyclin Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 208000006994 Precancerous Conditions Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/464449—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002361559A AU2002361559A1 (en) | 2001-09-24 | 2002-09-24 | Anticancer vaccine and diganostic methods and reagents |
EP02797036A EP1435776A4 (en) | 2001-09-24 | 2002-09-24 | Anticancer vaccine and diganostic methods and reagents |
US12/698,822 US8211436B2 (en) | 2001-09-24 | 2010-02-02 | Anticancer vaccine and diagnostic methods and reagents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32445001P | 2001-09-24 | 2001-09-24 | |
US60/324,450 | 2001-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003033520A2 WO2003033520A2 (en) | 2003-04-24 |
WO2003033520A3 true WO2003033520A3 (en) | 2004-02-19 |
Family
ID=23263637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/030289 WO2003033520A2 (en) | 2001-09-24 | 2002-09-24 | Anticancer vaccine and diganostic methods and reagents |
Country Status (4)
Country | Link |
---|---|
US (3) | US20030143647A1 (en) |
EP (1) | EP1435776A4 (en) |
AU (1) | AU2002361559A1 (en) |
WO (1) | WO2003033520A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050230315A1 (en) * | 2003-01-13 | 2005-10-20 | Regents Of The University Of Michigan | Protein microarray system |
US20030064527A1 (en) * | 2001-02-07 | 2003-04-03 | The Regents Of The University Of Michigan | Proteomic differential display |
US20080096284A1 (en) * | 2000-02-08 | 2008-04-24 | Regents Of The University Of Michigan | Protein separation and analysis |
AU2001234893A1 (en) * | 2000-02-08 | 2001-08-20 | The Regents Of The University Of Michigan | Protein mapping |
US20080153711A1 (en) * | 2000-02-08 | 2008-06-26 | Regents Of The University Of Michigan | Protein microarray system |
US6931325B2 (en) | 2001-02-07 | 2005-08-16 | Regents Of The University Of Michigan | Three dimensional protein mapping |
EP1435776A4 (en) * | 2001-09-24 | 2006-01-25 | Univ Pittsburgh | Anticancer vaccine and diganostic methods and reagents |
ATE405592T1 (en) * | 2003-01-13 | 2008-09-15 | Univ Michigan | METHOD FOR FORMING A PROTEIN MICROARRAY SYSTEM |
ES2247922A1 (en) * | 2004-05-07 | 2006-03-01 | Gianluca Cornetta | Integrated event management system using radio frequency for use in e.g. hotels, has central server with corresponding database that communicates with portable and remote terminals and with other peripheral devices using radio frequency |
WO2007044033A2 (en) | 2004-12-07 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen |
EP1864996A1 (en) * | 2006-06-06 | 2007-12-12 | Helmholtz-Zentrum für Infektionsforschung GmbH | Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker. |
WO2010011994A2 (en) | 2008-07-25 | 2010-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polypeptides and uses thereof |
JP6368243B2 (en) * | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | T-cell immunotherapy targeted to cyclin A1 for cancer |
FR3008099B1 (en) | 2013-07-05 | 2020-08-07 | Commissariat Energie Atomique | TUMOR ANTIGEN CYCLINE B1 IMMUNOGEN PEPTIDES |
US10023841B2 (en) * | 2014-05-23 | 2018-07-17 | Baylor Research Institute | Methods and compositions for treating breast cancer with dendritic cell vaccines |
KR20180040706A (en) * | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Immune cells having increased immunity or resistance to immunosuppressive cytokines and uses thereof |
EP4239653A1 (en) | 2017-02-01 | 2023-09-06 | Horton, Inc. | Electromagnetic coil connection assembly and associated method |
FR3090319A1 (en) | 2018-12-21 | 2020-06-26 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | MIXTURES OF CD8 T + EPITOPE CYCLINE B1 IMMUNOGENS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543291A (en) * | 1993-01-29 | 1996-08-06 | Dana Farber Cancer Institute | Method of detecting carcinoma |
US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
US5846827A (en) * | 1993-08-06 | 1998-12-08 | Cytel Corporation | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of CTL |
US5962318A (en) * | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
US5973119A (en) * | 1998-06-05 | 1999-10-26 | Amgen Inc. | Cyclin E genes and proteins |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE222291T1 (en) * | 1992-03-13 | 2002-08-15 | Organon Teknika Bv | EPSTEIN-BARR VIRUS RELATED PEPTIDES AND NUCLEIC ACID SEGMENTS |
US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
WO1996012406A1 (en) | 1994-10-19 | 1996-05-02 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
ES2203782T3 (en) * | 1996-01-17 | 2004-04-16 | Imperial College Innovations Limited | IMMUNOTHERAPY THAT USES CYTOTOXIC T LYMPHOCYTES (CTL). |
CA2279361A1 (en) * | 1997-01-31 | 1998-08-06 | Fred Hutchinson Cancer Research Center | Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e |
PT1066380E (en) | 1998-05-19 | 2002-05-31 | Avidex Ltd | T SOLUVEL CELL RECEIVER |
AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US20030040617A9 (en) * | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
US6225443B1 (en) * | 1999-05-19 | 2001-05-01 | Wisconsin Alumni Research Foundation | Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis |
EP1435776A4 (en) * | 2001-09-24 | 2006-01-25 | Univ Pittsburgh | Anticancer vaccine and diganostic methods and reagents |
US8143376B2 (en) | 2004-05-19 | 2012-03-27 | Immunocore Limited | High affinity NY-ESO T cell receptor |
WO2007044033A2 (en) | 2004-12-07 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen |
WO2010011994A2 (en) | 2008-07-25 | 2010-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polypeptides and uses thereof |
-
2002
- 2002-09-24 EP EP02797036A patent/EP1435776A4/en not_active Withdrawn
- 2002-09-24 AU AU2002361559A patent/AU2002361559A1/en not_active Abandoned
- 2002-09-24 US US10/253,867 patent/US20030143647A1/en not_active Abandoned
- 2002-09-24 WO PCT/US2002/030289 patent/WO2003033520A2/en not_active Application Discontinuation
-
2006
- 2006-03-02 US US11/366,196 patent/US7704507B2/en not_active Expired - Fee Related
-
2010
- 2010-02-02 US US12/698,822 patent/US8211436B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543291A (en) * | 1993-01-29 | 1996-08-06 | Dana Farber Cancer Institute | Method of detecting carcinoma |
US5846827A (en) * | 1993-08-06 | 1998-12-08 | Cytel Corporation | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of CTL |
US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
US5962318A (en) * | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
US5973119A (en) * | 1998-06-05 | 1999-10-26 | Amgen Inc. | Cyclin E genes and proteins |
Non-Patent Citations (4)
Title |
---|
BERARD F. ET AL.: "Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells", J. EXP. MED., vol. 192, no. 11, December 2000 (2000-12-01), pages 1535 - 1543, XP002964635 * |
COVINI G. ET AL.: "Immune response to cyclin B1 in hepatocellular carcinoma", HEPATOLOGY, vol. 25, no. 1, January 1997 (1997-01-01), pages 75 - 80, XP002968593 * |
HASSAN K.A. ET AL.: "Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue", CLINICAL CANCER RES., vol. 7, no. 8, August 2001 (2001-08-01), pages 2458 - 2462, XP002968591 * |
KIM H.K. ET AL.: "Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer", EUR. J. SURG. ONCOL., vol. 27, no. 5, August 2001 (2001-08-01), pages 464 - 471, XP002968592 * |
Also Published As
Publication number | Publication date |
---|---|
US20030143647A1 (en) | 2003-07-31 |
EP1435776A2 (en) | 2004-07-14 |
US7704507B2 (en) | 2010-04-27 |
US20100297158A1 (en) | 2010-11-25 |
AU2002361559A1 (en) | 2003-04-28 |
EP1435776A4 (en) | 2006-01-25 |
US8211436B2 (en) | 2012-07-03 |
WO2003033520A2 (en) | 2003-04-24 |
US20060147460A1 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003033520A3 (en) | Anticancer vaccine and diganostic methods and reagents | |
Zhivaki et al. | Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity | |
Carbone et al. | Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome | |
Markman et al. | Impact of the immune system and immunotherapy in colorectal cancer | |
ES2583754T3 (en) | Gene products differentially expressed in tumors and their use | |
Vacchelli et al. | Trial watch: Peptide vaccines in cancer therapy | |
Fotin‐Mleczek et al. | Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect | |
US20220160854A1 (en) | Composition and process for preparing vaccine | |
CN109789190A (en) | NANT cancer vaccine | |
CN102858964A (en) | Polypeptides | |
AU2001253079A1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
CN109125740A (en) | A kind of novel tumor vaccine and application thereof | |
KR20150013119A (en) | Treatment of non-small cell lung carcinoma by active immunotherapy | |
WO2001079286A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
US20230145817A1 (en) | Neoepitope vaccine and immune stimulant combinations and methods | |
CN101090633A (en) | Dendritic cell tumor injection (dcti) therapy | |
Kim et al. | Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells | |
WO2000052165A3 (en) | Compositions and methods for breast cancer therapy and diagnosis | |
IL262680B2 (en) | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy | |
Herbert et al. | Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors | |
US11564980B2 (en) | Tumor treatment method with an individualized peptide vaccine | |
Coosemans et al. | A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? | |
Huang et al. | Anti-tumor efficacy of an adjuvant built-in nanovaccine based on ubiquitinated proteins from tumor cells | |
CN104136040B (en) | Autologous cancer cell vaccine | |
KR20220029560A (en) | Novel cancer antigens and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002797036 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002797036 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002797036 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |